Thomas W LeBlanc1, Joanna M Smith2, David C Currow3. 1. Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Center for Learning Health Care, Duke Clinical Research Institute, Duke University, Durham, NC, USA. 2. Silver Chain Group, Perth, WA, Australia. 3. Discipline, Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia. Electronic address: david.currow@health.sa.gov.au.
Abstract
BACKGROUND: Patients with haematological malignancies are less likely to use palliative care services than are patients with solid tumours. This difference might stem from differing symptom burden, care needs, disease trajectories, or a combination of these factors. We described symptom burden and physical decline over time for people with haematological malignancies compared with people with solid tumours in a consecutive case series. METHODS: We included patients admitted to Silver Chain Hospice Care Service who died between Jan 1, 2011, and Dec 31, 2013, and who completed the eight-item Symptom Assessment Scale (0-10, with 0=no distress and 10=worst distress) at each clinical encounter. Physical function was assessed with the Australia-modified Karnofsky performance scale. Symptom and functional assessments were analysed at 7 days, 30 days, 60 days, and 90 days before death, by descriptive statistics. FINDINGS: We included 4638 participants. For people with haematological malignancies (n=224), the most troublesome symptoms were fatigue (mean score 5·2, SD 2·7) and loss of appetite (2·3, SD 2·9), and both worsened significantly near death (p=0·0035 for fatigue, p=0·016 for appetite). Other symptoms were often absent, and changed little over time. Compared with patients with solid tumours (n=4414), there were no significant differences in individual or cumulative symptom scores, changes over time, or the pattern of functional decline. INTERPRETATION: Community patients with haematological malignancies receiving palliative care have similar symptoms and patterns of physical decline at the end of life to people with solid tumours, suggesting similar care needs. This finding questions present limited palliative care service use by patients with haematological malignancies. FUNDING: None.
BACKGROUND:Patients with haematological malignancies are less likely to use palliative care services than are patients with solid tumours. This difference might stem from differing symptom burden, care needs, disease trajectories, or a combination of these factors. We described symptom burden and physical decline over time for people with haematological malignancies compared with people with solid tumours in a consecutive case series. METHODS: We included patients admitted to Silver Chain Hospice Care Service who died between Jan 1, 2011, and Dec 31, 2013, and who completed the eight-item Symptom Assessment Scale (0-10, with 0=no distress and 10=worst distress) at each clinical encounter. Physical function was assessed with the Australia-modified Karnofsky performance scale. Symptom and functional assessments were analysed at 7 days, 30 days, 60 days, and 90 days before death, by descriptive statistics. FINDINGS: We included 4638 participants. For people with haematological malignancies (n=224), the most troublesome symptoms were fatigue (mean score 5·2, SD 2·7) and loss of appetite (2·3, SD 2·9), and both worsened significantly near death (p=0·0035 for fatigue, p=0·016 for appetite). Other symptoms were often absent, and changed little over time. Compared with patients with solid tumours (n=4414), there were no significant differences in individual or cumulative symptom scores, changes over time, or the pattern of functional decline. INTERPRETATION: Community patients with haematological malignancies receiving palliative care have similar symptoms and patterns of physical decline at the end of life to people with solid tumours, suggesting similar care needs. This finding questions present limited palliative care service use by patients with haematological malignancies. FUNDING: None.
Authors: Catherine Henckel; Anna Revette; Scott F Huntington; James A Tulsky; Gregory A Abel; Oreofe O Odejide Journal: J Pain Symptom Manage Date: 2020-01-09 Impact factor: 3.612
Authors: Rong Wang; Amer M Zeidan; Stephanie Halene; Xiao Xu; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Cary P Gross; Steven D Gore; Xiaomei Ma Journal: J Clin Oncol Date: 2017-08-07 Impact factor: 44.544
Authors: Thomas W LeBlanc; Christine S Ritchie; Fred Friedman; Janet Bull; Jean S Kutner; Kimberly S Johnson; Arif H Kamal Journal: J Pain Symptom Manage Date: 2016-11-01 Impact factor: 3.612
Authors: Michael J Hochman; Yinxi Yu; Steven P Wolf; Greg P Samsa; Arif H Kamal; Thomas W LeBlanc Journal: J Pain Symptom Manage Date: 2017-09-05 Impact factor: 3.612
Authors: Steffen T Simon; Anne Pralong; Michael Hallek; Christoph Scheid; Udo Holtick; Marco Herling Journal: Ann Hematol Date: 2021-05-06 Impact factor: 3.673
Authors: Dorothy McCaughan; Eve Roman; Alexandra G Smith; Anne C Garry; Miriam J Johnson; Russell D Patmore; Martin R Howard; Debra A Howell Journal: BMC Palliat Care Date: 2018-02-21 Impact factor: 3.234